The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted therapies, the promise of off-the-shelf chimeric antigen receptor (CAR) ...
Five hundred forty-two specimens of 150 children enrolled in the AML-Berlin-Frankfurt-Muenster (BFM) 98 study were analyzed by four-color immunophenotyping at up to four predefined time points during ...
Early clearance of measurable residual disease (MRD) after induction therapy in patients with acute myeloid leukemia (AML) is associated with significantly better relapse-free survival (RFS) than ...
In this three-part webinar series, we invite you to explore the benefits of a standardized workflow in leukemia and lymphoma analysis. Join this showcase of Beckman Coulter’s new DxFLEX flow cytometer ...
The combination therapy, referred to as DAGO+m, yielded a 91% overall response rate and a promising 2-year overall survival ...
Our lab studies cell signaling and epigenetic pathways in an aggressive form of bone marrow cancer called acute myeloid leukemia (AML). Our primary focus is on a subtype of AML with mutations in FLT3, ...
CD37, a surface protein present on most acute myeloid leukemia (AML) blasts, demonstrates unique internalization properties that enable targeted drug delivery with minimal impact on normal blood cells ...
Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback